Clinical trial · Interventional
FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML
Fludarabine and Cytarabine as Continuous Infusion Plus Idarubicin With Granulocyte-Colony Stimulating Factor (G-CSF) Priming for Patients Younger Than 60 Years With Resistant Acute Myeloid Leukemia
NCT00559221CI-TRIAL-00001722unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
\- To determine the feasibility of fludarabine and cytarabine as continuous infusion plus idarubicin with granulocyte-colony stimulating factor priming for patients with resistant acute myeloid leukemia other than acute promyelocytic leukemia
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| FLAG+IDA | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- NO_INTERVENTION
- label
- 1
- interventionNames
- Drug: FLAG+IDA
Primary outcomes (1)
- measure
- Complete remission rate, duration of complete remission, toxicities
- timeFrame
- 06/2008
Secondary outcomes (1)
- measure
- progression-free survival, overall survival
- timeFrame
- 06/2008
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 15 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Failure to achieve CR after initial induction chemotherapy including standard dose cytarabine. * Early relapse, occurring after a first CR lasting less than 12 months. * Patients with multiple relapses will be included. * Written informed consent must be given. * 15 and 60 years of age. * 2 or less by ECOG performance scale. Exclusion Criteria: * acute promyelocytic leukemia * pregnant or lactating
References
Publications (1)
- DERIVEDKim H, Lee JH, Joo YD, Bae SH, Lee JH, Kim DY, Lee WS, Ryoo HM, Jo JC, Choi Y, Lee KH; CoOperative Study Group A for Hematology (COSAH). A prospective, multicenter phase II study of continuous infusion of FLAG for patients older than 60 yr with resistant acute myeloid leukemia: a comparison with intensive younger patients' trial. Eur J Haematol. 2016 Feb;96(2):188-97. doi: 10.1111/ejh.12568. Epub 2015 May 6. PMID 25891993